Jw Cayman Therapeutics Co Ltd (2126)

Currency in HKD
4.94
-0.34(-6.44%)
Delayed Data·
2126 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
2126 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.895.32
52 wk Range
1.196.44
Key Statistics
Bid/Ask
4.93 / 4.94
Prev. Close
5.28
Open
5.29
Day's Range
4.89-5.32
52 wk Range
1.19-6.44
Volume
3.6M
Average Volume (3m)
4.31M
1-Year Change
249.67%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2126 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.40
Downside
-51.47%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Jw Cayman Therapeutics Co Ltd Company Profile

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapy for use in the treatment of a range of hematological cancers, as well as systemic lupus erythematosus (SLE), a chronic autoimmune disease. The company’s products pipeline includes JWCAR129, a chimeric antigen receptor (CAR) construct therapy for use in the treatment of multiple myeloma; and JWCAR201, a dual targeting autologous CAR T-cell therapy for use in the treatment of B-cell malignancies and autoimmune diseases. It is also developing JWATM204 and JWATM214 for treating hepatocellular carcinoma (HCC); JWATM203 for the treatment of hepatoblastoma (HB) and hepatocellular carcinoma (HCC) in pediatric patients; JWATM213 for treating HCC; JWTCR001 for the treatment of various solid tumors; and JWCAR031 for the treatment of small cell lung cancer. In addition, the company engages in the drug research and development; medical research and experimental development; import and export handling; and clinical trial and CRO, as well as investment holding activities. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.

Compare 2126 to Peers and Sector

Metrics to compare
2126
Peers
Sector
Relationship
P/E Ratio
−3.3x−16.4x−0.5x
PEG Ratio
−0.130.290.00
Price/Book
1.7x6.3x2.6x
Price / LTM Sales
12.4x23.5x3.3x
Upside (Analyst Target)
−51.9%0.0%43.5%
Fair Value Upside
Unlock−8.0%6.9%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 2.40
(-51.47% Downside)

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
-0.85 / -0.72
Revenue / Forecast
71.40M / --
EPS Revisions
Last 90 days

2126 Income Statement

FAQ

What Stock Exchange Does Jw Cayman Trade On?

Jw Cayman is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Jw Cayman?

The stock symbol for Jw Cayman is "2126."

What Is the Jw Cayman Market Cap?

As of today, Jw Cayman market cap is 2.14B.

What Is Jw Cayman's Earnings Per Share (TTM)?

The Jw Cayman EPS (TTM) is -1.43.

From a Technical Analysis Perspective, Is 2126 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Jw Cayman Stock Split?

Jw Cayman has split 0 times.

How Many Employees Does Jw Cayman Have?

Jw Cayman has 281 employees.

What is the current trading status of Jw Cayman (2126)?

As of 07 Aug 2025, Jw Cayman (2126) is trading at a price of 4.94, with a previous close of 5.28. The stock has fluctuated within a day range of 4.89 to 5.32, while its 52-week range spans from 1.19 to 6.44.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.